Poolbeg Pharma (LON:POLB / OTCQB:POLBF) Investment Case with CEO Jeremy Skillington.
Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company with a unique capital light model. The company is focus on targeting the significant global medical need to treat and prevent infectious disease and has a growing pipeline of clinical stage products as well as a number of drug discovery platforms.
Artificial Intelligence (AI) has emerged as a transformative force in various industries, and the field of drug discovery is no exception. AI-powered technologies have revolutionized the way pharmaceutical research is conducted, accelerating the discovery and development of new
Poolbeg Pharma (AIM: POLB) has recruited three new members of its leadership team from Amryt Pharma, a fellow Anglo-Irish drugmaker with the same co-founder that was recently acquired by privately-held Italian drugmaker Chiesi. These experienced professionals will assume pivotal roles within
Poolbeg Pharma Plc (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that the Japanese Patent Office has notified the Company of its official decision
Artificial intelligence (AI) and machine learning (ML) technologies are redefining the way biopharma companies discover and develop drugs. It’s not a passing phase, either. Half of the 50 biggest pharmaceutical companies have entered into partnerships or licensing agreements with AI companies
Poolbeg Pharma (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that an abstract highlighting the potential of POLB 001 as a groundbreaking therapy has been accepted
Poolbeg Pharma announced the appointment of key former executives of Amryt Pharma plc (‘Amryt’) to its leadership team. These experienced professionals will assume pivotal roles within Poolbeg, further enhancing the Company’s expertise and capabilities. Poolbeg’s Chairman, Cathal Friel, co-founded both
Three members of Irish-based Amryt Pharma’s former leadership team are set to assume “pivotal roles” at London-headquartered pharma and biotech firm Poolbeg Pharma. David Allmond, John McEvoy and Laura Maher will join the company in the coming months. Allmond will become chief business officer
The discovery of new drugs has always been a challenging and expensive process. It involves extensive timeframes and significant costs, which have long highlighted the need for reform in this critical field. Despite previous efforts to accelerate drug
Poolbeg Pharma Plc (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced that an abstract detailing POLB 001’s promise as a potential treatment for Cytokine Release Syndrome associated with cancer immunotherapies has been accepted for
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
Poolbeg Pharma, a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced that it has signed a strategic collaboration agreement with a Nasdaq-listed biopharma company for the development of an optimised oral drug to
Poolbeg Pharma, a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it has signed a strategic collaboration agreement with a Nasdaq listed biopharma company for the development of an optimised oral drug to treat
The COVID-19 pandemic was an eye opener for the world on how quickly diseases and pathogens can emerge and spread globally, wreaking havoc on societies, economies, and healthcare systems. While the pharmaceutical industry scrambled for vaccines and treatments
Poolbeg Pharma plc (LON:POLB) a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced that its Scientific Advisory Board (‘SAB’) has endorsed the influenza drug targets identified in its AI-led drug discovery programme. Key highlights · Prioritisation of
Poolbeg Pharma has partnered with a Nasdaq-listed biopharma company on its oral delivery platform. The strategic collaboration will see both companies develop an optimised oral drug to treat a metabolic condition. Poolbeg said that it will receive funding
Organoids – living, 3D multicellular models of human organs – could revolutionize early research and discovery of new medicines. Because organoids mirror human biology more closely than animal models like mice and rats, they are ideal tools for
Strategic collaboration focussed on the development of an optimised drug for a metabolic condition using Poolbeg’s licensed oral delivery technology Collaboration may expand to a full licensing agreement Poolbeg Pharma (LON:POLB, OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with
The pharmaceutical industry has long been at the forefront of scientific innovation, driving advancements in medicine that aim to improve the quality of human health and lifespan. The race to develop vaccines and treatments for COVID-19 shows that
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.